We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Have you been eager to see how Citigroup (C - Free Report) performed in Q4 in comparison with the market expectations? Let’s quickly scan through the key facts from this New York-based money center bank’s earnings release this morning:
An Earnings Beat
Citigroup came out with adjusted earnings per share of $1.90, surpassing the Zacks Consensus Estimate of $1.82.
Rise in revenues were partially offset by higher operating expenses.
How Was the Estimate Revision Trend?
You should note that the earnings estimate for Citigroup depicted neutral stance prior to the earnings release. The Zacks Consensus Estimate remained stable over the last seven days.
Also, Citigroup has an impressive earnings surprise history. Before posting earnings beat in Q4, the company also delivered positive surprises in the prior four quarters. Overall, the company surpassed the Zacks Consensus Estimate by an average of 3.2% in the trailing four quarters.
Citigroup’s revenues of $18.4 billion beat the Zacks Consensus Estimate of $17.7 billion. Moreover, revenues grew 7% year over year.
Key Takeaways
Net income stood at $5 billion, up 15% from the prior year quarter.
Cost of credit rose 15% year over year to $2.2 billion.
Fixed income markets revenues jumped 49% year over year to $2.9 billion
Equity markets revenues of $516 million declined 23% from the prior-year quarter
Investment banking revenues grew 6% year over year to $1.4 billion
Returned $6.2 billion to shareholders as common stock repurchases and dividends during the quarter.
What Zacks Rank Says
The estimate revisions that we discussed earlier have driven a Zacks Rank #3 (Hold) for Citigroup. However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts.
Following the earnings release, Citigroup shares were up nearly 1% in the pre-trading session. This is in sync with to what the stock witnessed in the prior-day’s session. Clearly, the initial reaction shows that the investors have considered the results in their favor. However, the full-session’s price movement may indicate a different picture.
Check back later for our full write up on this Citigroup earnings report!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Citigroup's (C) Q4 Earnings & Revenues Beat Estimates
Have you been eager to see how Citigroup (C - Free Report) performed in Q4 in comparison with the market expectations? Let’s quickly scan through the key facts from this New York-based money center bank’s earnings release this morning:
An Earnings Beat
Citigroup came out with adjusted earnings per share of $1.90, surpassing the Zacks Consensus Estimate of $1.82.
Rise in revenues were partially offset by higher operating expenses.
How Was the Estimate Revision Trend?
You should note that the earnings estimate for Citigroup depicted neutral stance prior to the earnings release. The Zacks Consensus Estimate remained stable over the last seven days.
Also, Citigroup has an impressive earnings surprise history. Before posting earnings beat in Q4, the company also delivered positive surprises in the prior four quarters. Overall, the company surpassed the Zacks Consensus Estimate by an average of 3.2% in the trailing four quarters.
Citigroup Inc. Price and EPS Surprise
Citigroup Inc. price-eps-surprise | Citigroup Inc. Quote
Revenue Came In Better than Expected
Citigroup’s revenues of $18.4 billion beat the Zacks Consensus Estimate of $17.7 billion. Moreover, revenues grew 7% year over year.
Key Takeaways
What Zacks Rank Says
The estimate revisions that we discussed earlier have driven a Zacks Rank #3 (Hold) for Citigroup. However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts.
(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)
How the Market Reacted So Far
Following the earnings release, Citigroup shares were up nearly 1% in the pre-trading session. This is in sync with to what the stock witnessed in the prior-day’s session. Clearly, the initial reaction shows that the investors have considered the results in their favor. However, the full-session’s price movement may indicate a different picture.
Check back later for our full write up on this Citigroup earnings report!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>